지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
The FOLFOX-4 regimen as first-line treatment in patients with advanced gastric cancer has not evidence of category 1 for prolongation of survival in patients with advanced gastric cancer. Therefore, the use is preferred in the second line. But, especially in elderly patients, FOLFOX regimen was active and well tolerated with lower toxicities. Further phase III study is warranted to evaluate the evidence for prolongation of survival in elderly patients or combination therapy with target agents in advanced gastric cancer. (Korean J Med 2012;82:35-36)
목차
등록된 정보가 없습니다.
참고문헌 (4)
참고문헌 신청
Al-Batran SE / 2008 / Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, lecovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsg
Bang YJ / 201008 / Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cance
Cunningham D / 2008 / Capecitabine and oxaliplatin for advanced esophagogastric cancer / N Eng J Med 358 : 36 ~ 46
Louvet C / 2002 / Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients / J Clin Oncol 20 : 4543 ~ 4548
Bang YJ / 201008 / Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cance
Cunningham D / 2008 / Capecitabine and oxaliplatin for advanced esophagogastric cancer / N Eng J Med 358 : 36 ~ 46
Louvet C / 2002 / Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients / J Clin Oncol 20 : 4543 ~ 4548
이 논문의 저자 정보
최근 본 자료
댓글(0)
0